Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00KHD
|
||||
| Former ID |
DIB008847
|
||||
| Drug Name |
TAK-128
|
||||
| Synonyms |
Y-128
|
||||
| Indication | Diabetic neuropathy [ICD9: 250, 250.6, 356.0, 356.8; ICD10:E11.40] | Phase 2 | [1] | ||
| Company |
Mitsubishi Pharma Corp
|
||||
| Target and Pathway | |||||
| Target(s) | Thromboxane A2 receptor | Target Info | Modulator | [1] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Platelet activation | |||||
| Reactome | Prostanoid ligand receptors | ||||
| G alpha (q) signalling events | |||||
| G alpha (12/13) signalling events | |||||
| Thromboxane signalling through TP receptor | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Small Ligand GPCRs | |||||
| Signal amplification | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00229437) Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy. U.S. National Institutes of Health. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.